Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 with or without pembrolizumab versus physician's choice chemotherapy in HR-positive/HER2-negative advanced breast cancer
2023-504918-29-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 42
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan and pembrolizumab in breast cancer (3 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-504918-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504918-29-00.